免疫闪烁显像在直肠癌中的临床价值：直肠癌的免疫闪烁显像

Clinical value of immunoscintigraphy in the rectal carcinomas: immunoscintigraphy of rectal carcinomas.

作者信息

Petrovic Milorad, Jankovic Z, Jaukovic Lj, Artiko Vera, Šobic-Šaranovic Dragana, Antic Andrija, Žuvela Marinko, Radovanovic Nebojsa, Palibrk Ivan, Galun Danijel, Matic Slavko, Loncar Zlatibor, Bojovic Predrag, Ajdinovic Boris, Obradovic Vladimir

出版信息

Hepatogastroenterology. 2013 Sep;60(126):1355-9. doi: 10.5754/hge121035.

DOI:10.5754/hge121035

PMID:23340231

Abstract

BACKGROUND/AIM: The aim of this study was to evaluate the clinical reliability of the immunoscintigraphy with radiolabeled monoclonal antibodies for the detection of metastases and recurrences of rectal carcinomas.

METHODOLOGY

A total of 65 patients underwent immunoscintigraphy with radiolabeled monoclonal antibodies. Indication for that examination was suspicious rectal cancer or suspicious rectal cancer recurrence and/or metastases.

RESULTS

The method proved to have 92.7% sensitivity, specificity 83.3%, positive predictive value 90.5%, negative predictive value 87.0% and accuracy 89.2%. There was a statistically significant relationship between immunoscintigraphy findings and rectoscopy findings (rs=0.415, p=0.013), as well as significant relationship between immunoscintigraphy findings and US findings (rs=0.332, p=0.001). Tumor marker levels were in positive correlation with findings of immunoscintigraphy (rs=0.845, p=0.001), especially raised CEA level (rs=0.816, p=0.004). Patients with higher CA19-9 level had higher Duke's stage (p=0.025).

CONCLUSIONS

We can conclude that immunoscintigraphy can be helpful in the detection of metastases and recurrences of colon carcinomas.

摘要

背景/目的：本研究旨在评估放射性标记单克隆抗体免疫闪烁显像在检测直肠癌转移和复发方面的临床可靠性。

方法

共有65例患者接受了放射性标记单克隆抗体免疫闪烁显像检查。该项检查的指征为可疑直肠癌或可疑直肠癌复发和/或转移。

结果

该方法的敏感性为92.7%，特异性为83.3%，阳性预测值为90.5%，阴性预测值为87.0%，准确性为89.2%。免疫闪烁显像结果与直肠镜检查结果之间存在统计学显著相关性（rs = 0.415，p = 0.013），免疫闪烁显像结果与超声检查结果之间也存在显著相关性（rs = 0.332，p = 0.001）。肿瘤标志物水平与免疫闪烁显像结果呈正相关（rs = 0.845，p = 0.001），尤其是癌胚抗原（CEA）水平升高（rs = 0.816，p = 0.004）。糖类抗原19-9（CA19-9）水平较高的患者杜克分期较高（p = 0.025）。